Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland
Author(s)
Nicole Graf, MS1, Diana Teloian, MA2, Aastha Jain, MA3, Johan Maervoet, MBA, PhD4, César Oniangue-Ndza, PhD1.
1Bristol Myers Squibb, Steinhausen, Switzerland, 2PAREXEL, Tbilisi, Georgia, 3PAREXEL, Delhi, India, 4PAREXEL, Wavre, Belgium.
1Bristol Myers Squibb, Steinhausen, Switzerland, 2PAREXEL, Tbilisi, Georgia, 3PAREXEL, Delhi, India, 4PAREXEL, Wavre, Belgium.
Presentation Documents
OBJECTIVES: Non-small-cell lung cancer (NSCLC) accounts for 85% of approximately 4900 incident lung cancer cases (2800 in men and 2100 in women) diagnosed annually in Switzerland and is associated with short life expectancy. Despite the recent availability of targeted and immunotherapies, there remains a medical need for systemic treatments that can improve survival and quality of life for patients with metastatic NSCLC. The study objective was to estimate the budget impact of introducing nivolumab plus ipilimumab plus platinum-doublet chemotherapy (NIVO+IPI+PDC) as a first-line (1L) treatment for patients with untreated stage IV NSCLC without targetable gene alterations in Switzerland.
METHODS: A budget impact model was developed to compare scenarios with and without NIVO+IPI+PDC over a 5-year time horizon from a Swiss compulsory health insurance system perspective. Comparators included all drugs on the specialities list for this indication. Population size estimates utilized publicly available epidemiological data and market share estimates were based on market research and expert opinion. Drug prices were obtained from the FOPH list of specialties. Costs for drug administration, patient monitoring and management of adverse events were sourced from the inpatient (Swiss DRG) and outpatient (TARMED) tariff systems.
RESULTS: The introduction of NIVO+IPI+PDC for 1L NSCLC was estimated to increase costs by CHF 7.0 million to CHF 7.4 million in years 1 to 5, respectively. This corresponds to a budget impact of 5.1% over a 5-year time horizon. Scenario analyses suggested that the budget impact may range between 2.8% and 8.9%, depending on the product uptake.
CONCLUSIONS: The availability of NIVO+IPI+PDC would provide Swiss NSCLC patients and their treating physicians with a treatment option that can improve patient survival and quality of life. The budget impact for local approval and reimbursement of this regimen is expected to be modest and well within limits of what is generally deemed acceptable for an innovative therapy.
METHODS: A budget impact model was developed to compare scenarios with and without NIVO+IPI+PDC over a 5-year time horizon from a Swiss compulsory health insurance system perspective. Comparators included all drugs on the specialities list for this indication. Population size estimates utilized publicly available epidemiological data and market share estimates were based on market research and expert opinion. Drug prices were obtained from the FOPH list of specialties. Costs for drug administration, patient monitoring and management of adverse events were sourced from the inpatient (Swiss DRG) and outpatient (TARMED) tariff systems.
RESULTS: The introduction of NIVO+IPI+PDC for 1L NSCLC was estimated to increase costs by CHF 7.0 million to CHF 7.4 million in years 1 to 5, respectively. This corresponds to a budget impact of 5.1% over a 5-year time horizon. Scenario analyses suggested that the budget impact may range between 2.8% and 8.9%, depending on the product uptake.
CONCLUSIONS: The availability of NIVO+IPI+PDC would provide Swiss NSCLC patients and their treating physicians with a treatment option that can improve patient survival and quality of life. The budget impact for local approval and reimbursement of this regimen is expected to be modest and well within limits of what is generally deemed acceptable for an innovative therapy.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE111
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology